Health and Human Services Secretary Alex Azar explains why, despite comments to the contrary made by the US President, we have yet to see a voluntary reduction in drug prices by US pharmaceutical companies.
At a Senate Health, Education, Labor and Pensions hearing, Secretary Azar also discussed the issue of pharmacy benefit managers discouraging price list decreases, as well as the idea of using government regulations to prohibit rebates in order to reduce incentives for higher list prices. Explore more in this informative Pink Sheet article.
At a Senate Health, Education, Labor and Pensions hearing, Secretary Azar also discussed the issue of pharmacy benefit managers discouraging price list decreases, as well as the idea of using government regulations to prohibit rebates in order to reduce incentives for higher list prices. Explore more in this informative Pink Sheet article.
